Deutsche Bank Maintains Buy on ACADIA Pharmaceuticals, Raises Price Target to $38
ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc. ACAD | 0.00 |
Deutsche Bank analyst David Hoang maintains ACADIA Pharmaceuticals (NASDAQ:
ACAD) with a Buy and raises the price target from $37 to $38.